Orally available exendin

By forming a complex with incretin or its analogues and a hydrophobic ionic agent and encapsulating it in SEDDS, the problems of insufficient stability and bioavailability of oral formulations in the prior art are solved, and the effects of prolonged glycemic control and HbA1c reduction are achieved.

CN122318976APending Publication Date: 2026-06-30ALBUNEXT LLC
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ALBUNEXT LLC
Filing Date
2024-12-16
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing oral insulin and GLP-1 analog formulations have shortcomings in terms of stability and bioavailability, especially in cases where long-term blood glucose reduction is required, making it difficult to achieve effective blood glucose control.

Method used

Incretin or its analogues are combined with hydrophobic ionic agents to form hydrophobic ionic complexes, which are then encapsulated in a self-emulsifying drug delivery system (SEDDS). The lipid phase of the SEDDS is used for formulation to create a stable oral formulation.

Benefits of technology

It achieves prolonged glycemic control after oral administration, reduces blood glucose levels and HbA1c, and has stable drug release and improved bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122318976A_ABST
    Figure CN122318976A_ABST
Patent Text Reader

Abstract

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Oral administration of unstable or poorly-absorbed drugs

    US11331376B2

  • Albumin bound macromolecule tri-agonist activating GLP-1 / GIP / glucagon receptors

    US12576141B2

  • Composition for intraoral delivery of biologically active peptides and proteins

    US20180311146A1

  • Composition for orally administered formulation containing GLP-1 analogue

    US20240350590A1

  • Albumin Bound Macromolecule Tri-Agonist Activating GLP 1 / GIP / Glucagon Receptors And Methods Therefor

    US20240424072A1